Sanofi Agrees To Buy US-Based Amunix Pharma For $1B Upfront

Sanofi SA SNY will buy an immuno-oncology company, Amunix Pharmaceuticals Inc, for an upfront payment of about $1 billion.

  • Sanofi will also pay Amunix up to $225 million based on certain future development milestones.
  • "We are excited to advance Amunix's promising pipeline rapidly and to combine their innovative candidate medicines with complementary molecules in Sanofi's immuno-oncology portfolio," said John Reed, global head of research and development at Sanofi.
  • Earlier this year, Sanofi said it would buy two U.S. biotechs, Kadmon Holdings and Translate Bio, for $1.9 billion and $3.2 billion, respectively. 
  • Amunix's pipeline, which includes lead candidate AMX-818, a masked HER2-directed TCE, offers a strong strategic fit with Sanofi's focus on developing therapies in immuno-oncology. 
  • Sanofi expects to complete the acquisition in Q1 of 2022.
  • Price Action: SNY shares are up 0.61% at $49.27 during the premarket session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechM&ANewsHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!